Literature DB >> 29688413

Sex-Related Differences in Patients With Inflammatory Bowel Disease: Results of 2 Prospective Cohort Studies.

Mirjam Severs1, Lieke M Spekhorst2,3, Marie-Josée J Mangen4, Gerard Dijkstra2, Mark Löwenberg5, Frank Hoentjen6, Andrea E van der Meulen-de Jong7, Marieke Pierik8, Cyriel Y Ponsioen5, Gerd Bouma9, Janneke C van der Woude10, Mirthe E van der Valk1, Marielle J L Romberg-Camps11, Cees H M Clemens12, Paul van de Meeberg13, Nofel Mahmmod14, Jeroen Jansen15, Bindia Jharap16, Rinse K Weersma2, Bas Oldenburg1, Eleonora A M Festen1,2, Herma H Fidder1.   

Abstract

Background: The understanding of gender differences in inflammatory bowel disease (IBD) patients is an important step towards tailored treatment for the individual patient. The aim of this study was to compare disease phenotype, clinical manifestations, disease activity, and healthcare utilization between men and women with Crohn's disease (CD) and ulcerative colitis (UC).
Methods: Two multicenter observational cohort studies with a prospective design were used to explore the differences between men and women regarding demographic and phenotypic characteristics and healthcare utilization. Detailed data on IBD-phenotype was mainly available from the Dutch IBD Biobank, while the COIN cohort provided healthcare utilization data.
Results: In the Dutch IBD Biobank study, 2118 CD patients and 1269 UC patients were analyzed. Female CD patients were more often current smokers, and male UC patients were more often previous smokers. Early onset CD (<16 years) was more frequently encountered in males than in females (20% versus 12%, P < 0.01). Male CD patients were more often diagnosed with ileal disease (28% versus 20%, P < 0.01) and underwent more often small bowel and ileocecal resection. Extraintestinal manifestations (EIMs) were more often encountered in female IBD patients. In the COIN study, 1139 CD patients and 1213 UC patients were analyzed. Male CD patients used prednisone more often and suffered more often from osteopenia. IBD-specific healthcare costs did not differ between male and female IBD patients. Conclusions: Sex differences in patients with IBD include age of onset, disease location, and EIM prevalence. No large differences in therapeutic management of IBD were observed between men and women with IBD. 10.1093/ibd/izy004_video1izy004_Video_15786481854001.

Entities:  

Mesh:

Year:  2018        PMID: 29688413     DOI: 10.1093/ibd/izy004

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  14 in total

1.  Life expectancy and health-adjusted life expectancy in people with inflammatory bowel disease.

Authors:  M Ellen Kuenzig; Douglas G Manuel; Jessy Donelle; Eric I Benchimol
Journal:  CMAJ       Date:  2020-11-09       Impact factor: 8.262

2.  Dietary Chitin Particles Called Mimetic Fungi Ameliorate Colitis in Toll-Like Receptor 2/CD14- and Sex-Dependent Manners.

Authors:  Patricia Louis; Brian Mercer; Aiko M Cirone; Christina Johnston; Zachary J Lee; Nwadiuto Esiobu; Zhongwei Li; Jianning Wei; C Kathleen Dorey; Yoshimi Shibata; Changlong Nan
Journal:  Infect Immun       Date:  2019-04-23       Impact factor: 3.441

3.  Effects of ethnicity and socioeconomic status on surgical outcomes from inflammatory bowel disease.

Authors:  Dimitrios Stamatiou; David N Naumann; Helen Foss; Rishi Singhal; Sharad Karandikar
Journal:  Int J Colorectal Dis       Date:  2022-05-13       Impact factor: 2.571

4.  Ileitis-associated tertiary lymphoid organs arise at lymphatic valves and impede mesenteric lymph flow in response to tumor necrosis factor.

Authors:  Rafael S Czepielewski; Emma C Erlich; Emily J Onufer; Shannon Young; Brian T Saunders; Yong-Hyun Han; Mary Wohltmann; Peter L Wang; Ki-Wook Kim; Shashi Kumar; Chyi-Song Hsieh; Joshua P Scallan; Ying Yang; Bernd H Zinselmeyer; Michael J Davis; Gwendalyn J Randolph
Journal:  Immunity       Date:  2021-11-16       Impact factor: 31.745

5.  Glucocorticoids and Androgens Protect From Gastric Metaplasia by Suppressing Group 2 Innate Lymphoid Cell Activation.

Authors:  Jonathan T Busada; Kylie N Peterson; Stuti Khadka; Xiaojiang Xu; Robert H Oakley; Donald N Cook; John A Cidlowski
Journal:  Gastroenterology       Date:  2021-05-07       Impact factor: 33.883

6.  A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia.

Authors:  Norfilza Mohd Mokhtar; Khairul Najmi Muhammad Nawawi; Jaarvis Verasingam; Wong Zhiqin; Ismail Sagap; Zairul Azwan Mohd Azman; Luqman Mazlan; Hamzaini Abdul Hamid; Nur Yazmin Yaacob; Isa Mohamed Rose; Eden Low Ngah Den; Mah Suit Wan; Raja Affendi Raja Ali
Journal:  BMC Public Health       Date:  2019-06-13       Impact factor: 3.295

Review 7.  Sex-based differences in inflammatory bowel diseases: a review.

Authors:  Sheila D Rustgi; Maia Kayal; Shailja C Shah
Journal:  Therap Adv Gastroenterol       Date:  2020-04-28       Impact factor: 4.409

8.  Risk factors and prognostic value of acute severe lower gastrointestinal bleeding in Crohn's disease.

Authors:  Jiyoung Yoon; Dae Sung Kim; Ye-Jee Kim; Jin Wook Lee; Seung Wook Hong; Ha Won Hwang; Sung Wook Hwang; Sang Hyoung Park; Dong-Hoon Yang; Byong Duk Ye; Jeong-Sik Byeon; Seung-Jae Myung; Suk-Kyun Yang
Journal:  World J Gastroenterol       Date:  2021-05-21       Impact factor: 5.742

9.  Elderly-onset vs adult-onset ulcerative colitis: a different natural history?

Authors:  Irene Zammarchi; Francesco Lanzarotto; Rosanna Cannatelli; Francesca Munari; Federica Benini; Alessandro Pozzi; Alberto Lanzini; Chiara Ricci
Journal:  BMC Gastroenterol       Date:  2020-05-12       Impact factor: 3.067

10.  Tooth loss and adiposity: possible role of carnitine transporter (OCTN1/2) polymorphisms in women but not in men.

Authors:  Peter Meisel; Stefanie Pagels; Markus Grube; Gabriele Jedlitschky; Henry Völzke; Thomas Kocher
Journal:  Clin Oral Investig       Date:  2020-09-22       Impact factor: 3.573

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.